Sundry Photography/iStock Editorial via Getty Images
Johnson & Johnson (NYSE:JNJ) said it has submitted a New Drug Application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer.
The drugmaker is seeking to have the therapy approved for